{{medical}}
{{DiseaseDisorder infobox
| Name           = Sclerosis
| ICD10          = {{ICD10|M|34||m|30}}
| ICD9           = {{ICD9|710.1}}
| ICDO           =
| Image          =
| Caption        =
| OMIM           = 181750
| MedlinePlus    = 000429
| eMedicineSubj  = med
| eMedicineTopic = 2076
| eMedicine_mult = {{eMedicine2|med|3132}} {{eMedicine2|derm|677}} {{eMedicine2|ped|2197}}
| DiseasesDB     = 12845
| MeshID         = D012595
}}
'''硬皮病'''（{{lang-en|Scleroderma}}），也称'''全身性硬化症（{{lang|en|Systemic sclerosis}}）'''，根據皮膚侵犯的區域，分為只限皮膚症狀不會侵犯內臟系統的局部型（{{lang|en|localized scleroderma}}）或會侵犯內臟系統的全身性硬化症（Systemic sclerosis；SSc）。<ref>{{Cite book|chapter=Systemic Sclerosis|title=Primer on the Rheumatic Diseases|url=http://dx.doi.org/10.1007/978-0-387-68566-3_17|publisher=Springer New York|date=2008|location=New York, NY|isbn=978-0-387-35664-8|pages=343–362|first=Maureen D.|last=Mayes}}</ref>這是一种以限制性（{{lang|en|limited systemic form}}）或弥漫性（{{lang|en|diffuse systemic form}}）[[皮肤|皮肤]]增厚、變硬和內臟纤维化为特征的全身性[[自體免疫性疾病|自體免疫疾病]]。病变特点为皮肤纤维細胞增生明顯、膠原纖維增多及洋葱皮狀外觀上的改变，最终导致皮肤硬化、血管缺血，除皮肤受累外，它也可影响[[内脏|内脏]]（心、[[肺|肺]]和[[消化道|消化道]]等器官）。女性发病率为男性的3～4倍。

硬皮症皮膚表徵較為明顯，因此大多數人通常較在意皮膚方面的症狀，忽略了真正導致死亡的其實是其他器官如肺部的侵犯，如肺動脈高壓與間質性肺病；其中，最常併發的間質性肺病為肺纖維化，會阻礙肺泡間正常的氣體交換，導致肺功能下降、死亡率增加，無法回復到正常狀態。因此硬皮症患者應隨時留意自己的肺部健康，一旦出現長達2個月的咳、喘或累等症狀，應主動告知醫師。

== 體徵與症状 ==

=== 分期 ===
硬皮病的疾病可分為五期：

免疫系統失調：某些因素觸發免疫系統的變化，導致遺傳中易感性高的個體應中病相關致病因子的發展

循環致病因素：變動後的免疫系統會持續產生破壞性的自身抗體或其他致病因子

微血管內皮損傷：自身抗體或其他循環制娉因子直接或間接對為血管內皮層造成反覆創傷

纖維化：內皮的反覆創傷及修復會造成纖維化的進展

器官受損：纖維化最終影響到器官系統，包含皮膚或其他內部器官

=== 症狀 ===
心血管疾病：患者初期肢端會有明顯[[雷諾氏現象|雷諾氏現象]]<ref name="#1">{{Cite journal|title=硬皮症之診斷治療新進展|last=陳依伶|last2=梁培英|date=2016-01-01|doi=10.6314/jimt.2016.27(1).04|language=zh-TW|last3=魏正宗|last4=許人文}}</ref>，且95%硬皮症患者有[[雷诺氏综合征|雷諾氏症候群症狀]]；指尖[[潰瘍|潰瘍]]；皮膚、粘膜有[[蛛網紋|蜘蛛網狀靜脈曲張現象]]<ref>{{Cite journal|title=Review: Evidence That Systemic Sclerosis Is a Vascular Disease|url=http://dx.doi.org/10.1002/art.37988|last=Matucci-Cerinic|first=Marco|last2=Kahaleh|first2=Bashar|date=2013-07-26|journal=Arthritis & Rheumatism|issue=8|doi=10.1002/art.37988|volume=65|pages=1953–1962|issn=0004-3591|last3=Wigley|first3=Fredrick M.}}</ref> ; 出現不規則的心律造成[[心悸|心悸]]甚至昏厥。

消化系統：[[胃食道逆流|胃食道逆流]]、腹脹、消化不良、食慾不振、腹瀉與便秘，[[乾燥症|乾燥症候群]]與其併發症。

肺部疾病：[[間質性肺病|間質性肺病]]、肺動脈高壓。肺纖維化為最常併發的一種間質性肺病，會阻礙肺泡間正常的氣體交換，導致肺功能下降、死亡率增加，無法回復到正常狀態。<ref>{{Cite journal|title=Fibrotic Cytokine Interplay in Evaluation of Disease Activity in Treatment Naïve Systemic Sclerosis Patients from Western India|url=https://www.ncbi.nlm.nih.gov/pubmed/31562712|last=Khadilkar|first=Prasad V.|last2=Khopkar|first2=Uday S.|date=2019-08|journal=The Journal of the Association of Physicians of India|issue=8|volume=67|pages=26–30|issn=0004-5772|pmid=31562712|last3=Nadkar|first3=Milind Y.|last4=Rajadhyaksha|first4=Anjali G.|last5=Chougule|first5=Durga A.|last6=Deshpande|first6=Sunita D.|last7=Madkaikar|first7=Manisha R.|last8=Pradhan|first8=Vandana D.}}</ref>肺動脈高壓臨床上亦為硬皮症患者的不良預後因子，有肺動脈高壓的硬皮症患者，若沒有接受治療1、2、3年的存活率分別為 81%、64%、52%。<ref>{{Cite journal|title=Survival and Prognostic Factors in Systemic Sclerosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis|url=http://dx.doi.org/10.1002/art.38029|last=Lefèvre|first=Guillaume|last2=Dauchet|first2=Luc|date=2013-08-26|journal=Arthritis & Rheumatism|issue=9|doi=10.1002/art.38029|volume=65|pages=2412–2423|issn=0004-3591|last3=Hachulla|first3=Eric|last4=Montani|first4=David|last5=Sobanski|first5=Vincent|last6=Lambert|first6=Marc|last7=Hatron|first7=Pierre-Yves|last8=Humbert|first8=Marc|last9=Launay|first9=David}}</ref>

硬皮症腎危機（SRC）：在過去，腎臟病變是硬皮症併發症中預後最不好的一種，會導致突發性惡性高血壓與急性腎衰竭，在台灣統計發生率約佔所有硬皮症患者 2.5%。<ref>{{Cite journal|title=Scleroderma Renal Crisis: A Rare Complication of Systemic Sclerosis with Poor prognosis-experience in a Medical Center in Central Taiwan|last=陳建行|last2=陳怡行|date=2007-12-01|doi=10.6313/fjr.2007.21(02).10|language=en|last3=藍忠亮|last4=陳得源}}</ref>近年來在ACEi, CCB, ARB的使用之下，以大大的提升患者預後。

肌肉骨骼：關節，肌肉酸痛，[[腕隧道症候群|腕隧道症候群]]和肌肉無力。<ref>{{Cite journal|title=Prevalence of carpal tunnel syndrome in a general population|url=https://www.ncbi.nlm.nih.gov/pubmed/10411196|last=Atroshi|first=I.|last2=Gummesson|first2=C.|date=1999-07-14|journal=JAMA|issue=2|doi=10.1001/jama.282.2.153|volume=282|pages=153–158|issn=0098-7484|pmid=10411196|last3=Johnsson|first3=R.|last4=Ornstein|first4=E.|last5=Ranstam|first5=J.|last6=Rosén|first6=I.|access-date=2020-03-25|archive-date=2020-04-15|archive-url=https://web.archive.org/web/20200415000154/https://www.ncbi.nlm.nih.gov/pubmed/10411196|dead-url=no}}</ref>

泌尿生殖系統：勃起功能障礙，性交困難，腎臟問題或腎功能衰竭。

其他：三叉神經痛、頭痛、中風、疲勞，和體重減輕引起的面部疼痛。<ref>{{Cite book|edition=18th ed.|chapter=Harrison's principles of internal medicine.|url=https://www.worldcat.org/oclc/288932926|publisher=McGraw-Hill|date=2012|location=New York|isbn=978-0-07-174889-6|oclc=288932926|last=Longo, Dan L. (Dan Louis), 1949-|title=|access-date=2020-03-25|archive-date=2020-02-18|archive-url=https://web.archive.org/web/20200218190540/https://www.worldcat.org/title/harrisons-principles-of-internal-medicine/oclc/288932926|dead-url=no}}</ref><ref>{{Cite journal|title=Classification Criteria for Systemic Sclerosis: An ACR-EULAR Collaborative Initiative|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930146/|last=van den Hoogen|first=Frank|last2=Khanna|first2=Dinesh|date=2013-11|journal=Arthritis and rheumatism|issue=11|doi=10.1002/art.38098|volume=65|pages=2737–2747|issn=0004-3591|pmc=3930146|pmid=24122180|last3=Fransen|first3=Jaap|last4=Johnson|first4=Sindhu R.|last5=Baron|first5=Murray|last6=Tyndall|first6=Alan|last7=Matucci-Cerinic|first7=Marco|last8=Naden|first8=Raymond|last9=Riemekasten|first9=Gabriela|access-date=2020-03-25|archive-date=2021-10-30|archive-url=https://web.archive.org/web/20211030220955/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930146/|dead-url=no}}</ref>


根據2013年美國風濕病學會、歐洲風濕病聯盟共同制定的分類標準，若患者的臨床表徵及免疫學檢測符合以下情況，總評分為9分以上可判定為系統性硬皮症。<ref>{{Cite journal|title=2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative|url=https://onlinelibrary.wiley.com/doi/abs/10.1002/art.38098|last=Hoogen|first=Frank van den|last2=Khanna|first2=Dinesh|date=2013|journal=Arthritis & Rheumatism|issue=11|doi=10.1002/art.38098|volume=65|pages=2737–2747|language=en|issn=1529-0131|pmc=PMC3930146|pmid=24122180|last3=Fransen|first3=Jaap|last4=Johnson|first4=Sindhu R.|last5=Baron|first5=Murray|last6=Tyndall|first6=Alan|last7=Matucci‐Cerinic|first7=Marco|last8=Naden|first8=Raymond P.|last9=Medsger|first9=Thomas A.|access-date=2020-03-25|archive-date=2021-04-17|archive-url=https://web.archive.org/web/20210417042841/https://onlinelibrary.wiley.com/doi/abs/10.1002/art.38098|dead-url=no}}</ref>
{| class="wikitable"
| colspan="2" |臨床表徵及免疫學檢測
|分數
|-
|皮膚變硬、增厚，從雙手掌指關節伸延至身體近端
|<nowiki>-</nowiki>
|9
|-
| rowspan="2" |手指皮膚增厚
|手指腫脹
|2
|-
|指端硬化
|4
|-
| rowspan="2" |指尖病變
|指尖潰瘍
|2
|-
|指尖凹陷性疤痕
|3
|-
|毛細血管擴張
|<nowiki>-</nowiki>
|2
|-
|甲褶微血管鏡異常
|<nowiki>-</nowiki>
|2
|-
| rowspan="2" |肺動脈高壓/肺間質纖維化
|肺動脈高壓
|2
|-
|肺間質纖維化
|2
|-
|雷諾氏現象
|<nowiki>-</nowiki>
|3
|-
| rowspan="3" |硬皮症相關免疫抗體
|Anti-centromere 
|3
|-
|Anti-topoisomerase I（Scl-70）
|3
|-
|Anti-RNA polymerase III
|3
|}
=== 原因 ===
硬皮病目前推論由遺傳和環境因素引起<ref>{{Cite journal|title=Epidemiology of systemic sclerosis|url=http://dx.doi.org/10.1097/bor.0b013e32834ff2e8|last=Barnes|first=Jammie|last2=Mayes|first2=Maureen D.|date=2012-03|journal=Current Opinion in Rheumatology|issue=2|doi=10.1097/bor.0b013e32834ff2e8|volume=24|pages=165–170|issn=1040-8711}}</ref><ref>{{Cite journal|title=The Immune Pathogenesis of Scleroderma: Context Is Everything|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539168/|last=Greenblatt|first=Matthew B.|last2=Aliprantis|first2=Antonios O.|date=2013-1|journal=Current rheumatology reports|issue=1|doi=10.1007/s11926-012-0297-8|volume=15|pages=297|issn=1523-3774|pmc=3539168|pmid=23288576}}</ref><ref>{{Cite journal|title=Scleroderma – New aspects in pathogenesis and treatment|url=http://www.sciencedirect.com/science/article/pii/S1521694212000125|last=Balbir-Gurman|first=Alexandra|last2=Braun-Moscovici|first2=Yolanda|date=2012-02-01|journal=Best Practice & Research Clinical Rheumatology|issue=1|doi=10.1016/j.berh.2012.01.011|series=New Pearls on CTDs|volume=26|pages=13–24|language=en|issn=1521-6942}}</ref><ref>{{Cite journal|title=Environmental risk factors in systemic sclerosis:|url=http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00002281-201303000-00005|last=Dospinescu|first=Paula|last2=Jones|first2=Gareth T.|date=2013-03|journal=Current Opinion in Rheumatology|issue=2|doi=10.1097/BOR.0b013e32835cfc2d|volume=25|pages=179–183|language=en|issn=1040-8711|last3=Basu|first3=Neil}}</ref>，環境因素指的是人類白血球抗原HLA基因突變後某些情況下接觸了二氧化矽、芳族、氯化溶劑、酮、三氯乙烯、焊接煙霧和石油溶劑，可能導致硬皮症的發生。<ref>{{Cite journal|title=Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature|url=http://www.sciencedirect.com/science/article/pii/S1568997213001778|last=Marie|first=I.|last2=Gehanno|first2=J. -F.|date=2014-02-01|journal=Autoimmunity Reviews|issue=2|doi=10.1016/j.autrev.2013.10.002|volume=13|pages=151–156|language=en|issn=1568-9972|last3=Bubenheim|first3=M.|last4=Duval-Modeste|first4=A. -B.|last5=Joly|first5=P.|last6=Dominique|first6=S.|last7=Bravard|first7=P.|last8=Noël|first8=D.|last9=Cailleux|first9=A. -F.}}</ref>

=== 治療 ===
目前硬皮症無法完全治癒，但可緩解症狀。 

根據專家共識建議以下治療方式： 

硬皮症腎危機（{{lang|en|scleroderma renal crisis}}, SRC）：一線治療可採用[[血管紧张肽I转化酶抑制剂|血管紧张肽I转化酶抑制剂]]，二線採用[[钙离子通道阻滞剂|钙离子通道阻滞剂]]、[[血管紧张素II受体拮抗剂|血管紧张素II受体拮抗剂]]。

肺動脈高壓：治療使用內皮素受體激動劑（ERAs）、[[第五型磷酸二酯酶抑制劑|第五型磷酸二酯酶抑制劑]]，或是[[前列腺素|前列腺素]]。嚴重PAH將會採用上述藥物組合治療。

[[雷诺氏综合征|雷诺氏综合征]]：可透過血管擴張劑、鈣離子通道阻滯劑<ref>{{Cite journal|title=Raynaud's Phenomenon of the Nipple: A Treatable Cause of Painful Breastfeeding|url=http://pediatrics.aappublications.org/cgi/doi/10.1542/peds.113.4.e360|last=Anderson|first=J. E.|last2=Held|first2=N.|date=2004-04-01|journal=PEDIATRICS|issue=4|doi=10.1542/peds.113.4.e360|volume=113|pages=e360–e364|language=en|issn=0031-4005|last3=Wright|first3=K.}}</ref>、[[第五型磷酸二酯酶抑制劑|第五型磷酸二酯酶抑制劑]]、[[血管紧张素II受体拮抗剂|血管紧张素II受体拮抗剂]]、[[前列腺素|前列腺素]]，單獨或是合併使用。

間質性肺病：過去常用的治療藥物為[[环磷酰胺|環磷醯胺]]治療，或是使用[[黴酚酸|黴酚酸酯]]<ref>{{Cite journal|title=Effect of Mycophenolate Mofetil on Pulmonary Function in Scleroderma-Associated Interstitial Lung Disease|url=http://dx.doi.org/10.1378/chest.06-2861|last=Gerbino|first=Anthony J.|last2=Goss|first2=Christopher H.|date=2008-02|journal=Chest|issue=2|doi=10.1378/chest.06-2861|volume=133|pages=455–460|issn=0012-3692|last3=Molitor|first3=Jerry A.}}</ref>，針對傳統免疫抑制藥物治療反應不佳病人可使用 anti CD20 Rituximab治療。<ref>{{Cite journal|title=Rituximab in severe, treatment-refractory interstitial lung disease|url=http://dx.doi.org/10.1111/resp.12214|last=Keir|first=Gregory J.|last2=Maher|first2=Toby M.|date=2013-11-29|journal=Respirology|issue=3|doi=10.1111/resp.12214|volume=19|pages=353–359|issn=1323-7799|last3=Ming|first3=Damien|last4=Abdullah|first4=Reza|last5=de Lauretis|first5=Angelo|last6=Wickremasinghe|first6=M.|last7=Nicholson|first7=Andrew G.|last8=Hansell|first8=David M.|last9=Wells|first9=Athol U.}}</ref>2019最新研究指出[[尼達尼布|尼達尼布]]可減緩硬化症所引發的間質性肺病。研究中試驗組與對照組相比，前者可有效減緩44%肺部功能衰退，相關研究已於2019年美國胸腔學會（ATS）發表<ref>{{Cite journal|title=Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease|url=http://www.nejm.org/doi/10.1056/NEJMoa1903076|last=Distler|first=Oliver|last2=Highland|first2=Kristin B.|date=2019-06-27|journal=New England Journal of Medicine|issue=26|doi=10.1056/NEJMoa1903076|volume=380|pages=2518–2528|language=en|issn=0028-4793|last3=Gahlemann|first3=Martina|last4=Azuma|first4=Arata|last5=Fischer|first5=Aryeh|last6=Mayes|first6=Maureen D.|last7=Raghu|first7=Ganesh|last8=Sauter|first8=Wiebke|last9=Girard|first9=Mannaig|access-date=2020-04-09|archive-date=2020-07-24|archive-url=https://web.archive.org/web/20200724140847/https://www.nejm.org/doi/10.1056/NEJMoa1903076|dead-url=no}}</ref><ref>{{Cite journal|title=Scleroderma lung disease|url=http://dx.doi.org/10.1183/09059180.00005512|last=Solomon|first=J. J.|last2=Olson|first2=A. L.|date=2013-02-28|journal=European Respiratory Review|issue=127|doi=10.1183/09059180.00005512|volume=22|pages=6–19|issn=0905-9180|last3=Fischer|first3=A.|last4=Bull|first4=T.|last5=Brown|first5=K. K.|last6=Raghu|first6=G.}}</ref>，同年9月美國FDA亦通過[[尼達尼布|尼達尼布]]用於延緩系统性硬化症相關間質性肺疾病（SSc-ILD）的肺部功能惡化<ref>{{Cite web|title=FDA approves first treatment for patients with rare type of lung disease|url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-rare-type-lung-disease|accessdate=2020-04-09|date=2020-03-24|last=Commissioner|first=Office of the|work=FDA|language=en|archive-date=2020-03-10|archive-url=https://web.archive.org/web/20200310043320/https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-rare-type-lung-disease|dead-url=no}}</ref>。台灣治療部分，2020年3月已通過該藥將適用於減緩與全身性硬化症有關之間質性肺病病人的肺功能下降速度。

腸胃道症狀建議可以使用[[氫離子幫浦阻斷劑|氫離子幫浦阻斷劑]]來預防胃食道逆流、食道潰瘍與食道狹窄等症狀。<ref>{{Cite journal|title=Treatment of Systemic Sclerosis Complications: What to Use When First-Line Treatment Fails—A Consensus of Systemic Sclerosis Experts|url=http://www.sciencedirect.com/science/article/pii/S0049017212000170|last=Walker|first=Kyle M.|last2=Pope|first2=Janet|date=2012-08-01|journal=Seminars in Arthritis and Rheumatism|issue=1|doi=10.1016/j.semarthrit.2012.01.003|volume=42|pages=42–55|language=en|issn=0049-0172}}</ref>

=== 預後 ===
全身性硬皮病的5年生存率約為85％，而10年生存率則接近70％<ref>{{Cite journal|title=Systemic sclerosis – dermatological aspects. Part 1: Pathogenesis, epidemiology, clinical findings|url=https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1610-0387.2012.07999.x|last=Sticherling|first=Michael|date=2012|journal=JDDG: Journal der Deutschen Dermatologischen Gesellschaft|issue=10|doi=10.1111/j.1610-0387.2012.07999.x|volume=10|pages=705–716|language=en|issn=1610-0387}}</ref>，根據子類型而有所不同。硬皮病主要死因為肺部的侵犯，如肺動脈高壓與間質性肺病，其中，最常併發的間質性肺病為肺纖維化。<ref name="#1"/>硬皮症患者併有間質性肺病後，其存活中位數僅剩5至8 年。另外，硬皮病患者罹患癌症（尤其是肝癌，肺癌，血液學和膀胱癌）和心血管疾病的風險也較高。<ref>{{Cite journal|title=The Prevalence of Atherosclerosis in Those with Inflammatory Connective Tissue Disease by Race, Age and Traditional Risk Factors|url=http://dx.doi.org/10.1038/srep20303|last=Alenghat|first=Francis J.|date=2016-02-04|journal=Scientific Reports|issue=1|doi=10.1038/srep20303|volume=6|issn=2045-2322}}</ref><ref>{{Cite journal|title=Cardiovascular disease in systemic sclerosis - an emerging association?|url=http://dx.doi.org/10.1186/ar3445|last=Ngian|first=Gene-Siew|last2=Sahhar|first2=Joanne|date=2011|journal=Arthritis Research & Therapy|issue=4|doi=10.1186/ar3445|volume=13|pages=237|issn=1478-6354|last3=Wicks|first3=Ian P|last4=Van Doornum|first4=Sharon}}</ref><ref>{{Cite journal|title=Malignancies associated with systemic sclerosis|url=http://www.sciencedirect.com/science/article/pii/S1568997212000493|last=Szekanecz|first=Éva|last2=Szamosi|first2=Szilvia|date=2012-10-01|journal=Autoimmunity Reviews|issue=12|doi=10.1016/j.autrev.2012.02.021|volume=11|pages=852–855|language=en|issn=1568-9972|last3=Horváth|first3=Ágnes|last4=Németh|first4=Ágnes|last5=Juhász|first5=Balázs|last6=Szántó|first6=János|last7=Szücs|first7=Gabriella|last8=Szekanecz|first8=Zoltán}}</ref>

== 扩展条目 ==
* [[成纤维细胞|成纤维细胞]]

== 参考资料 ==
{{Reflist}}

== 外部連結 ==
* {{en}}[http://dermnetnz.org/immune/systemic-sclerosis.html DermnetNZ: Systemic sclerosis] {{Wayback|url=http://dermnetnz.org/immune/systemic-sclerosis.html |date=20080115185006 }}
* {{en}}[http://www.jsdn.org/ Juvenile Scleroderma Network] {{Wayback|url=http://www.jsdn.org/ |date=20080111024225 }}
* {{en}}[http://www.juvenile-scleroderma.com/ Juvenile Systemic Sclerosis] {{Webarchive|url=https://archive.is/20130103151745/http://www.juvenile-scleroderma.com/ |date=2013-01-03 }}
* {{en}}[http://www.scleroderma.org/ Scleroderma Foundation] {{Wayback|url=http://www.scleroderma.org/ |date=20071010183337 }}
* {{en}}[http://www.sclerodermaontario.ca/ Scleroderma Society of Ontario] {{Wayback|url=http://www.sclerodermaontario.ca/ |date=20080129124416 }}
* {{en}}[http://www.sclero.org/index.html International Scleroderma Network] {{Wayback|url=http://www.sclero.org/index.html |date=20080113153542 }}
* {{en}}[http://www.sclerodermaresearch.org/ The Scleroderma Research Foundation] {{Wayback|url=http://www.sclerodermaresearch.org/ |date=20080515193849 }}
* {{en}}[http://www.sclerodermasociety.co.uk/ UK Scleroderma Society] {{Wayback|url=http://www.sclerodermasociety.co.uk/ |date=20071015044611 }}
* {{en}}[https://web.archive.org/web/20121210192045/http://www.0580gb.com/ UK Scleroderma Society]
* {{en}}[http://scleroderma.jhmi.edu/ Scleroderma Information from Johns Hopkins University] {{Wayback|url=http://scleroderma.jhmi.edu/ |date=20080205021142 }}

{{系统性结缔组织疾病}}

[[Category:皮膚和皮下組織疾病|Category:皮膚和皮下組織疾病]]

[[no:Sklerose|no:Sklerose]]
[[ru:Системная_склеродермия|ru:Системная склеродермия]]
[[sr:Sistemska_skleroza|sr:Sistemska skleroza]]
[[uk:Системна_склеродермія|uk:Системна склеродермія]]